Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

Cardiac Allograft Vasculopathy Clinical Trial

Official title:

Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation (CTOT-11)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01278745
• Other study ID #: DAIT CTOT-11
• Status: Terminated
• Phase: Phase 2
• Start date: September 2011
• Est. completion date: October 2015

Study information

• Verified date: August 2020
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

All people who have a heart transplant are at risk for developing cardiac allograft vasculopathy (CAV). CAV means narrowing of the heart transplant vessels, which is associated with poor heart transplant function. People who develop antibodies after transplant have a higher risk of developing CAV. Infections, high cholesterol, and rejection also increase the risk of developing CAV. People who develop CAV usually have to receive another transplant.

Description:

The purpose of this research study is to see if a study drug called rituximab (Rituxan®) prevents CAV. Rituximab destroys certain types of white blood cells called B cells. B cells are important cells in the immune system that help the body fight infection by producing substances called antibodies. B cells and the antibodies they produce are also involved in some kinds of rejection after organ transplantation. Rituximab decreases the number of B cells in the blood and other tissues. The goal of this study is to determine if decreasing B cells with Rituximab can prevent injury to the transplanted heart.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 362
• Est. completion date: October 2015
• Est. primary completion date: October 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria for Initial Enrollment:

• Subject must be able to understand and provide informed consent;

• Male or Female, 18 to 75 years of age;

• Candidate for a primary heart transplant (e.g., listed for heart transplant only);

• Historical panel reactive antibodies (PRA) less than 30%;

• Calculated GFR = 40 mL/minute using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI);

• Female and male subjects with reproductive potential, must agree to use FDA approved methods of birth control for the duration of the study

Inclusion Criteria for Randomization / Post-transplant:

--Negative PRA within 12 weeks prior to transplant (Local HLA Center Testing) using one of the following:

• One Lambda's LABScreen® Mixed Class I & II (presence or absence), or

• Less than 10% by One Lambda's LABScreen® PRA Class I and II with an MFI of <2000, or

• Calculated panel reactive antibodies (cPRA) less than 10% by LABScreen® Single Antigen testing (Anti-HLA-A, -B, -DR, -DQ). The antigens reported will include those with an MFI >2000.

The Luminex Gen-Probe beads are equivalent to the One Lambda and may be used as an alternative;

• Calculated GFR = 40mL/minute using the CKD-EPI at time of randomization;

• Serum immunoglobulin G (IgG) level greater than 500mg/dL within 90 days prior to randomization;

• Negative test for HIV, HBsAg, HBcAb, and HCV Ab within 12 months prior to transplant. If documentation is not present to support that the testing was performed in the past 12 months, then a blood sample will be collected prior to transplant and sent for local testing. Results may be available after randomization. If positive result, the oversight committee will review the case and provide further recommendations.

• Female subjects of childbearing potential must have a negative pregnancy test.

Exclusion Criteria for Enrollment:

• Prior history of organ transplantation;

• Previous treatment with Rituximab (MabThera® / Rituxan ®);

• Transplant physician intention to use any induction agents;

• History of severe allergic anaphylactic reactions to humanized or murine monoclonal antibodies;

• History of severe reaction to previous therapy with IVIG;

• Active systemic infection at time of enrollment;

• Any history of serologic positivity to HIV, HBsAg, HBcAb, and HCV Ab;

• History of less than 5 years remission of malignancy. Any history of adequately treated in-situ cervical carcinoma, or adequately treated basal or squamous cell carcinoma of the skin will be permitted;

• Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;

• Use of other investigational drugs within 4 weeks of enrollment;

• Currently breast-feeding or plans to become pregnant during the timeframe of the study follow-up period.

Exclusion Criteria for Randomization/Post-transplant:

• Recipient of multiple solid organ or tissue transplants;

• Previous treatment with Rituximab (MabThera® / Rituxan ®);

• Use of any induction agents;

• History of severe allergic anaphylactic reactions to humanized or murine monoclonal antibodies;

• History of severe reaction to previous therapy with IVIG; Lack of IV venous access;

• Active systemic infection at time of randomization;

• Any history of serologic positivity to HIV, HBsAg, HBcAb and HCV Ab;

• Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;

• Use of other investigational drugs within 4 weeks prior to randomization;

• Receipt of a live vaccine within 30 days prior to randomization;

• Currently breast-feeding or plans to become pregnant during the timeframe of the study follow-up period.

Related Conditions & MeSH terms

• Cardiac Allograft Vasculopathy
• Heart Transplant Recipients
• Vascular Diseases

Intervention

Biological:
• Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)

Drug:
• Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)

Locations

Country	Name	City	State
United States	University of Maryland	Baltimore	Maryland
United States	Cedars Sinai Heart Institute	Beverly Hills	California
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Tufts Medical Center	Boston	Massachusetts
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Northwestern University	Chicago	Illinois
United States	Cleveland Clinic Foundation	Cleveland	Ohio
United States	Medical City Dallas Hospital/CRSTI	Dallas	Texas
United States	The Methodist Hospital	Houston	Texas
United States	Ronald Regan UCLA Medical Center	Los Angeles	California
United States	University of Wisconsin	Madison	Wisconsin
United States	Minneapolis Heart Institute	Minneapolis	Minnesota
United States	University of Minnesota	Minneapolis	Minnesota
United States	Intermountain Medical Center	Murray	Utah
United States	Columbia University Medical Center	New York	New York
United States	Mount Sinai School of Medicine	New York	New York
United States	Stanford University/Palo Alto VA	Palo Alto	California
United States	Drexel University College of Medicine	Philadelphia	Pennsylvania
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Allegheny General Hospital	Pittsburgh	Pennsylvania
United States	University of Utah	Salt Lake City	Utah
United States	University of California San Francisco	San Francisco	California
United States	Stanford University	Stanford	California

Sponsors (5)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Clinical Trials in Organ Transplantation, Genentech, Inc., National Heart, Lung, and Blood Institute (NHLBI), Rho Federal Systems Division, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Starling RC, Armstrong B, Bridges ND, Eisen H, Givertz MM, Kfoury AG, Kobashigawa J, Ikle D, Morrison Y, Pinney S, Stehlik J, Tripathi S, Sayegh MH, Chandraker A; CTOT-11 Study Investigators. Accelerated Allograft Vasculopathy With Rituximab After Cardiac — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Percent Atheroma Volume (PAV)	Nominal or noticeable change, bad or good, from baseline to 1 year in percent atheroma volume (PAV) which is a measure of the degree of coronary arterial obstruction due to host alloimmune processes measured by intravascular ultrasound (IVUS) in a target coronary artery. Thus a decrease in PAV would be an indicator of less obstruction and a better outcome.	Baseline, 1 year
Secondary	Death	Participants who died within 12 months post-transplant	12 months
Secondary	Re-transplantation or Re-listed for Transplantation	Re-transplantation is defined as the receipt of a subsequent heart transplant and re-listed for transplantation is being listed back on the heart transplant list to be re-transplanted.	6 to 12 months
Secondary	Number of Episodes of Biopsy Proven Acute Rejection (BPAR) of Any Grade Per Participant	The number of times a participant experienced biopsy proven acute rejection (BPAR). Biopsy proven acute rejection is when an examination of tissue removed from the transplanted organ indicates that the subject's immune system is trying to reject the graft. BPAR was defined as a biopsy that met the International Society for Heart & Lung Transplantation (ISHLT) criteria to be graded as 1R or greater rejection and was determined by a single, central pathology laboratory.	6 to 12 months
Secondary	Incidence of BPAR (Any Grade)	The number of subjects who experienced any grade of biopsy proven acute rejection (BPAR) within the clinical trial. Biopsy proven acute rejection is when an examination of tissue removed from the transplanted organ indicates that the subject's immune system is trying to reject the graft. BPAR was defined as a biopsy which met The International Society for Heart & Lung Transplantation (ISHLT) criteria to be graded as 1R or greater rejection and was determined by a single, central pathology laboratory.	6 to 12 months
Secondary	Incidence of AMR	The number of participants who experienced antibody- mediated rejection (AMR). Antibody-mediated rejection (AMR) occurs when the subject develops antibodies directed against the transplanted heart. This was assessed based on local pathology biopsy reads.	6 to 12 months
Secondary	Incidence of Cellular Rejection	Cellular Rejection refers to the organ recipient's immune system recognizing a transplanted organ as foreign and mounting a response to it via cellular mechanisms. Cellular rejection was defined as a biopsy which met The International Society for Heart & Lung Transplantation (ISHLT) criteria to be graded as 1R or greater rejection and was determined by a single, central pathology laboratory	6 to 12 months
Secondary	Incidence of Any Treated Rejection	The number of participants who were treated by their local physician for any type of rejection including, but not limited to cellular rejection and antibody- mediated rejection (AMR) of the transplanted heart regardless of the presence of a biopsy.	6 to 12 months
Secondary	Number of Participants With Episodes of Rejection Associated With Hemodynamic Compromise (HDC)	The number of participants that experienced at least one episode of rejection associated with hemodynamic compromise (HDC). Rejection associated with HDC is when there is insufficient blood flow to the transplanted heart in association with acute rejection found in a biopsy. Local biopsies were used for this outcome measure.	6 to 12 months
Secondary	Number of Participants With Development of Angiographically Evident Cardiac Allograft Vasculopathy	Cardiac allograft vasculopathy is an aggressive form of atherosclerosis that is characterized by the development of fibrosis affecting cardiac arteries that result in concentric narrowing of the arteries and, ultimately allograft failure. Development of cardiac allograft vasculopathy can be diagnosed via an angiograph which is an X-ray of the cardiac arteries by injecting a radiopaque substance such as iodine.	1 year
Secondary	Number of Participants With Post-transplant Serious Infections Requiring Intravenous Antimicrobial Therapy	Number of participants experiencing at least one serious infection requiring intravenous antimicrobial therapy which is used to kill the growth of microorganisms such as bacteria, fungi, or protozoans.	Transplantation through end of study, up to 1 year post transplantation.
Secondary	Number of Participants With Post-transplant Incidence of PTLD	The number of participants experiencing at least one post-transplant lymphoproliferative disorder (PTLD) occurrence during this trial. Post-transplant lymphoproliferative disorder is an uncontrolled proliferation of B cell lymphocytes latently infected with Epstein-Barr virus.	Transplantation through end of study, up to 1 year post transplantation.
Secondary	Post-transplant Safety Outcomes Among Participants: Safety and Tolerability of Rituximab	Defined as participants that experienced at least one adverse event that was possibly, probably, or definitely related to the study drug (i.e., Rituximab or Placebo). Serious adverse events were used to evaluate this endpoint and the attribution was based on the DAIT Medical Monitor's assessment.	Transplantation through end of study, up to 1 year post transplantation

External Links

•   Clinical Trials in Organ Transplantation (CTOT) website
•   National Heart, Lung, and Blood Institute (NHLBI) website
•   National Institute of Allergy and Infectious Diseases (NIAID) website